Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Abdulla A. Damluji, MD, PhD Profile picture
@DrDamluji
Nov 4, 2021 • 5 tweets • 4 min read • Read on X
Scrolly
EROSION III

OCT vs angiography

Study population: STEMI

Randomized 1:1

Outcomes MACCE at 1 month and 1 year

#TCT2021
Results
Secondary endpoint and procedural data
Limitations
Conclusions

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Abdulla A. Damluji, MD, PhD

Abdulla A. Damluji, MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrDamluji

Abdulla A. Damluji, MD, PhD Profile picture
Aug 13
Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial: @ESC_Journals

🥸Aspirin for primary prevention for older pts = MACE!

👇👇👇👇 Image
🥸1️⃣ ASPREE was a large randomized trial designed to evaluate whether daily low-dose aspirin prevents cardiovascular events in initially healthy older adults.
🥸2️⃣ ASPREE enrolled 19,114 community-dwelling adults ≥70 (≥65 for US minorities), free of prior cardiovascular disease, dementia, or disability. Participants were randomized to 100 mg aspirin or placebo and followed in-trial (median 4.7 yrs) and post-trial (median 4.3 yrs).
Read 21 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Aug 6
Acute coronary syndromes: mechanisms, challenges, and new opportunities: @ESC_Journals

🥸Very nice review -

😱Many research questions

👇👇👇 Image
🥸1️⃣ Acute coronary syndromes remain a leading cause of global mortality, with one out of three deaths attributed to atherosclerosis and its acute or chronic complications.
🥸2️⃣ Most ACS events are caused by coronary plaque rupture or plaque erosion, but other mechanisms include calcific nodules, embolism, spontaneous coronary artery dissection (SCAD), coronary spasm, and microvascular dysfunction. Image
Read 22 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Jul 15
Mitral valve replacement or repair and long-term risk of infective endocarditis: a Danish nationwide study: @ESC_Journals

🥸Nice study - mitral valve replacement and infective endocarditis during follow-up

👇👇👇 Image
🥸1️⃣ This Danish nationwide cohort study examined the 10-year risk of first-time infective endocarditis (IE) in patients after mitral valve (MV) replacement or repair, compared to those at moderate risk of IE, using high-quality registry data from 2000–2020.
🥸2️⃣ The study included 1220 patients who underwent isolated MV replacement, 3239 who underwent MV repair, and 209,517 categorized as moderate risk of IE (such as those with CIEDs, congenital valve anomalies, HCM, rheumatic or degenerative valve disease).
Read 21 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Jun 9
Alcohol Use and Cardiovascular Disease: A Scientific Statement From the American Heart Association: @CircAHA

🥸 Great work from @AHAScience

😱 No level of alcohol is truly “safe”: Summary

👇👇👇 Image
🥸1️⃣ Alcohol use and cardiovascular disease (CVD) have a complicated and often debated relationship; this AHA statement reviews decades of research on coronary artery disease (CAD), stroke, heart failure (HF), arrhythmias, and cardiomyopathy.
🥸2️⃣ Most evidence linking alcohol and CVD is observational, with strong risks for bias and confounding; randomized trials are rare, and definitive answers are lacking.
Read 22 tweets
Abdulla A. Damluji, MD, PhD Profile picture
May 13
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: @NEJM

🥸 SURMOUNT-5 Trial: Wow!

😱 Summary

👇👇👇 Image
🥸 1️⃣ SURMOUNT-5 directly compares tirzepatide and semaglutide for obesity in adults without diabetes. First head-to-head randomized trial of these two GLP-1–based agents. Published @NEJM, May 2025.

[DOI: 10.1056/NEJMoa2416394]
🥸 2️⃣ 751 adults with BMI ≥30 or ≥27 + 1 comorbidity (HTN, dyslipidemia, OSA, or CVD) were randomized to tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) once weekly for 72 weeks. No participants had type 2 diabetes.
Read 22 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Apr 29
Healthy ageing in older adults with cardiovascular disease: @ESC_Journals

🥸 So proud of Nathalie, Jon & @KritiKalra092 for their hard work

😱 With my friend @MichaelGNanna in published in the European Heart Journal

🥸What is healthy aging? How do we achieve it?

👇👇👇 Image
🥸 1️⃣ Healthy ageing in cardiovascular disease matters because by 2050, adults 65+ will represent over 20% of the U.S. and nearly 30% of Europe's population, dramatically shifting healthcare needs.
🥸 2️⃣ Cardiovascular disease already leads all causes of death globally, and as populations age, CVD-related disability and healthcare costs will keep rising.
Read 24 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(